Table 4.
Prognosis in 2 years after liver transplantation
| MSC (N = 11) | Rituximab (N = 11) | P value | |
|---|---|---|---|
| Survival rate no. (%) | 9 (81.8%) | 8 (72.7%) | 1.000 |
| Graft survival rate no. (%) | 9 (81.8%) | 8 (72.7%) | 1.000 |
| Acute rejection no. (%) | 1 (9.1%) | 3 (27.3%) | 0.586 |
| Biliary complications no. (%) | 0 (0%) | 5 (45.5%) | 0.035a |
| Ischemia type biliary lesion no. (%) | 0 (0%) | 4 (36.4%) | 0.090 |
| Bile duct anastomotic stenosis no. (%) | 0 (0%) | 3 (27.3%) | 0.214 |
| Bile leakage no. (%) | 0 (0%) | 1 (9.1%) | 1.000 |
| Septic shock no. (%) | 1 (9.1%) | 9 (81.8%) | 0.002b |
| Pulmonary infection no. (%) | 0 (0%) | 8 (72.7%) | 0.001b |
| Biliary infection no. (%) | 0 (0%) | 1 (9.1%) | 1.000 |
| Splenic abscess no. (%) | 1 (9.1%) | 0 (0%) | 1.000 |
| Arteriostenosis no. (%) | 1 (8.3%) | 3 (27.3%) | 0.586 |
| De novo tumor no. (%) | 0 (0%) | 1 (9.1%) | 1.000 |
aP < 0.05, bP < 0.01
Abbreviations: MSC mesenchymal stem cell